Adeno-associated virus (AAV) production services
Your trusted partner in AAV development and manufacturing
With over two decades of experience, we are industry leaders specializing in a comprehensive array of capabilities for AAV vectors across multiple serotypes.
We’ve manufactured AAV for a total of:
300+ total batches
190+ clinical batches
45+ commercial/PPQ batches
Thermo Fisher Scientific prides itself on cutting-edge capabilities, ensuring the seamless production of AAV vectors with expertise in both natural and novel serotypes. To meet the unique needs of our clients, we employ state-of-the-art technologies using triple transfection in both adherent and suspension cell cultures (mammalian and insect cell lines) as well as producer cell line based viral production and cell line cloning.
- Quality assurance: Quality is the cornerstone of our operations. Our rigorous quality assurance measures ensure the production of AAV vectors that meet and exceed regulatory standards, providing you with the utmost confidence in the reliability of our services.
- Collaboration opportunities: We believe in the power of collaboration. Thermo Fisher Scientific is eager to explore partnerships and collaborations to drive innovation and advance the field of gene therapy. Let's work together to bring your vision to fruition.
- Team expertise: Our team consists of dedicated professionals with diverse expertise in AAV development and manufacturing. From seasoned researchers to skilled technicians, we bring a collective wealth of knowledge to ensure the success of your AAV program.
Our team is experienced in supporting a variety of other viral platforms. For questions about our additional capabilities and capacity, please contact us.
AAV experience with both natural and novel serotypes
Helpful Resources
Whitepaper
Evaluating current manufacturing platforms for recombinant AAV production
Realizing the full potential of viral vector-based therapies requires a successful manufacturing platform for recombinant Adeno-associated virus (AAV) vectors.
Blog
A CDMO Partner for every Gene Therapy Manufacturing Stage
Take a closer look at the experiences of NysnoBio and bluebird bio for insight into what companies need in a CDMO partner for every stage of viral vector manufacturing and development.
Fact Sheet
Viral vector development and manufacturing services
Thermo Fisher Scientific provides over 20 years of unparalleled experience in developing and manufacturing viral vector products. We specialize in addressing the complexities of viral vector production for cell and gene therapies, including challenges related to production system selection, product quality optimization, and standardization for a robust CMC approach.
Blog
Viral vector commercialization – Part 1: Tech transfer process for commercial viral vector manufacturing
Learn how tech transfers can help develop and manufacture viral vectors at scale, accelerate vaccine and gene therapy commercialization, and provide expertise.
Blog
Viral vector commercialization – Part 2: Best practices in process validation lifecycle
Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.
Webinar
Benefits of an integrated approach to gene therapy development and manufacturing
Learn about the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner.
View Webinar
Article
Strategies to accelerate drug development through harmonization of early and late stage processes
This technical article presents a harmonized and streamlined approach established at Thermo Fisher Scientific for manufacturing AAV and LV vectors for discovery research using technologies and processes mirroring current GMP platforms.
View Article
Webinar
Preparing viral vector productions for commercialization
Gene therapy vectors are rapidly approaching the commercial space so commercial readiness is critical for success. Watch our webinar to learn about our capabilities and approaches for preparing viral vectors for commercialization.
View Webinar
Infographic
Regulatory pathways for CGT and ATMP products
CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.
View Infographic
eBook
Cell and gene therapies in the US vs. the EU: Top five areas of differentiation
In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.